Safety in Ovarian Cancer for Average-Risk Women - Analysis

This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women. Participants will provide a blood sample for screening and will be followed for approximately 12 months to assess test safety, specificity, downstream diagnostic procedures, and ovarian cancer outcomes.

Inclusion Criteria: * Postmenopausal women with one or both ovaries * Age 50 years or more * No personal history of ovarian cancer * No hereditary cancer syndrome of genetic risk factors associated with ovarian cancer * Willingness to allow medical record review * Willingness to have blood drawn * Ability to provide informed consent Exclusion Criteria: * Removal of both ovaries for any reason * Known genetic risk factors associated with ovarian cancer or hereditary cancer syndrome * Pregnant or breastfeeding * Currently under clinical surveillance due to a known or suspected elevated risk of developing ovarian cancer * Women who are symptomatic and being evaluated for ovarian cancer * Current untreated malignancy (other than non-melanoma skin cancer) * Currently receiving adjuvant chemotherapy or radiation therapy for cancer. Patients who are being treated may enroll 3 months after completion of last treatment. * Anticoagulant use (self-reported) * Known conditions posing unacceptable phlebotomy risk (self-reported) * Unwilling to provide the name of primary care physician or provider * Unwilling to sign informed consent and/or medical records release form.